Human trophoblast cell-surface antigen-2 (Trop-2) is a membrane glycoprotein involved in cell proliferation and motility, frequently overexpressed in epithelial tumors. Thus, it represents an attractive target for anticancer therapies. Sacituzumab govitecan (SG) is a third-generation antibody-drug conjugate (ADC), consisting of an anti-Trop-2 monoclonal antibody (hRS7), a hydrolysable linker, and a cytotoxin (SN38), which inhibits topoisomerase 1. Specific pharmacological features, such as the high antibody to payload ratio, the ultra-toxic nature of SN38, and the capacity to kill surrounding tumor cells (the bystander effect), make SG a very promising drug for cancer treatment. Moreover, unprecedented results have been observed with SG in patients with heavily pretreated advanced triple-negative breast cancer and hormone-positive/HER2-negative metastatic breast cancer, and the drug has already received approval for these indications in Taiwan.
從台灣到全球、從預防到治療
2014年吉立亞醫藥在台灣成立分公司，相信更健康的世界，來自更健康的生命，一路走來與病友同行，從生命到生活，結合科學與創新，與政府單位和社群組織攜手合作，開創生命的健康樣貌。
吉立亞醫藥始終創造第一，在愛滋病毒由預防到治療的旅途上，打造了完整的照顧旅程。在病毒性肝炎上，也推出 C型肝炎全口服抗病毒藥物，更有針對新冠病毒的治療藥物，讓新興傳染病不再是健康的破口。2023年正式跨足癌症治療領域，希望能夠解決更多未被滿足的治療需求。
Creating possible是吉立亞醫藥的信念，更是每個員工的信仰，從台灣到全球，從預防到治療，吉立亞醫藥持續在生命的不可能中，創造更多的可能。